14 MS Experimental Therapies You Should Know About

Click here to receive MS news via e-mail
news_11_new_Artboard 343 copy 92

news_11_Artboard 343 copy 92

1. ALKS 8700

Alkremes Inc. is developing a novel formulation called ALKS 8700 to treat demyelinating neurodegenerative disorders of the central nervous system such as multiple sclerosis (MS).

Learn more about ALKS 8700.

2. AP-1

Ankar Pharmaceuticals, a Spanish-Filipino start-up in biopharmaceuticals, has been working on the development of their premier drug candidate for treating multiple sclerosis (MS), called AP-1. The unique property of this pipeline drug is its ability to excel in terms of prophylactic measures in people suspected to be affected by the condition, as well as in those with a full-blown case history of MS and relapses. This gives the oral formulation an advantageous edge over many contemporary drugs, fingolimod being the latest to be approved, for treating MS.

Learn more about AP-1.

Tagged .

Andreia has a degree in New Communication Technologies and experience in social media, design and tech. She is eager to find new ways to communicate and explore her curiosity about science and technology.
Click here to receive MS news via e-mail

One comment

Leave a Comment

Your email address will not be published. Required fields are marked *